Fig. 2From: Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyThe incorporation (%) of 213Bi-DOTATATE 71 ± 28 MBq determined by ITLC analysis as function of peptide amount in a reaction volume of 800 μL. An S-shaped cureve has been fitted through the data with an incorporation of 50 % at 2.4 ± 0.09 nmol and a slope of 0.25 ± 0.03 nmol peptide, n ≥ 3Back to article page